Essential Tremor and a History of Asthma: Propranolol, Primidone, or Neither
The better-studied first-line drug for tremor carries a real respiratory risk for this specific patient, and the alternative has its own real tolerability problem.
Diane K., 66, taught piano out of her home for over thirty years and still plays for two hours most evenings, though the tremor in both hands — present in some form since her forties, her mother and grandmother had it too — has progressively worsened over the past three years to the point where fast passages have become genuinely difficult to execute cleanly, not just less polished. She has essential tremor, confirmed by exam (a postural and kinetic tremor, worse with sustained arm extension and action, no rest component, no other parkinsonian features), consistent with the family history she describes across three generations. She has mild persistent asthma, diagnosed in her thirties, well controlled for years on a combination inhaled corticosteroid/long-acting beta-agonist inhaler, with one hospitalization for an exacerbation roughly a decade ago and none since.
Propranolol, a nonselective beta-blocker, is one of two first-line options with genuine evidence behind it for essential tremor, working by blocking peripheral beta-2 receptors in skeletal muscle that contribute to tremor amplitude — a mechanism distinct from, and largely independent of, the tremor's actual central origin, still incompletely understood but thought to involve abnormal oscillatory activity in cerebello-thalamo-cortical circuits. That peripheral, nonselective blockade is exactly what makes it a real concern in a patient with asthma: beta-2 blockade in airway smooth muscle a nonselective agent doesn't spare can precipitate bronchospasm, and even one exacerbation in a patient with a hospitalization history a decade ago is a documented, not merely theoretical, risk she carries. Primidone, an anticonvulsant metabolized in part to phenobarbital, works through an entirely different, still not fully characterized mechanism thought to involve GABAergic potentiation, and carries no comparable pulmonary risk. The American Academy of Neurology's practice parameter on essential tremor (Zesiewicz et al.) gives propranolol and primidone the same Level A recommendation as first-line therapy, which is precisely why her asthma, rather than any difference in expected efficacy, is what decides between them — but it comes with its own real first-dose problem: acute sedation, dizziness, and nausea severe enough at a standard starting dose that many patients who can't tolerate it stop before ever reaching an effective maintenance dose, a failure pattern well described enough that standard practice is now to start far below the eventual target dose and titrate slowly upward over weeks.
Clinic, worsening tremor over three years
Propranolol is nonselective — it blocks beta-2 receptors in her airway smooth muscle the same way it blocks the peripheral beta-2 receptors in skeletal muscle responsible for its tremor-reducing effect. She has mild persistent asthma with a real hospitalization a decade ago, not just a diagnosis on paper. I wouldn't start it. Primidone doesn't carry that pulmonary risk, and I'd make it first-line here specifically because of her asthma, not because it's the stronger drug on average.
I agree propranolol's off the table given her history. My concern with primidone is different: at a standard starting dose, a real number of patients get hit with enough first-dose sedation, dizziness, and nausea that they stop before ever reaching a dose that actually helps. Koller and Vetere-Overfield (1989) found acute adverse reactions in 32% of patients on primidone versus 8% on propranolol in a direct head-to-head comparison — that gap is exactly the dropout risk I'm describing, and it would leave her right back where she started, just having tried and failed a drug we knew carried that risk.
I'd want a genuinely conservative starting dose written into the plan explicitly, not just 'primidone, titrate up' — the standard practice now is to start well below the eventual target and go slow specifically to avoid exactly that dropout.
Before we finalize primidone, I want to close off an option that sounds like an easy middle path but isn't: a cardioselective beta-blocker, like metoprolol, doesn't carry the same asthma risk, but the tremor-reducing effect of this drug class is specifically tied to nonselective beta-2 blockade. Cardioselective agents haven't shown comparable efficacy for essential tremor — it isn't a safe substitute, it's a different drug that doesn't actually do the job.
Agreed, unanimously: start primidone at a conservative dose with slow titration and close early follow-up specifically to catch first-dose intolerance early enough to adjust rather than have her abandon the drug. Propranolol and cardioselective substitutes both explicitly ruled out and documented in her chart, so the reasoning doesn't need to be re-litigated at a future visit by a clinician who doesn't know her asthma history.